Home > Jobs > 2010 > BioInformatics Scientist


BioInformatics Scientist open

AVEO Pharmaceuticals, Inc.
75 Sidney Street, 4th Floor
Cambridge, MA  02139
BioInformatics Scientist
Reports to: Manager Bioinformatics

Job Code: 10-TR25
Department: Translational Research
Location: Cambridge, MA

We are seeking a highly motivated, independent bioinformatics scientist to join a group of scientists, analysts and programmers to develop tools and methodologies for large-scale gene expression data analysis.  The group supports a variety of research projects in target and drug discovery as well as biomarker development for AVEO's growing pipeline of novel anti-cancer drugs,

AVEO's Translational Research program utilizes a novel platform combining proprietary, inducible tumor models and bioinformatics approaches to discover, validate and generate therapeutics against molecular targets in oncology.  We have generated large populations of tumors that exhibit inter-tumor heterogeneity similar to that seen in human tumor populations. Each tumor has been characterized by microarray, array CGH, histology, key signaling pathways as well as sensitivity to a variety of cancer therapeutics, including AVEO's clinical stage drug candidates.  This well-characterized tumor population model system enables the correlation of gene expression and DNA copy number with drug efficacy, providing an attractive platform for the creative innovative bioinformatics scientist to develop and test translational hypotheses. Our goal is  to use the platform to inform clinical trial design regarding tumor, tumor subtype and patient selection for AVEO's own clinical stage oncology drug candidates.

The candidate will:
*    Participate in generating, processing and evaluating large oncology-related datasets. 
*    Work on a variety of high-dimensional data projects largely centered on biomarker discovery and develop biomarkers for response to therapy and disease subtype classification
*    Execute a wide range of computational and analytical tasks, including developing and implementing algorithms for target identification and biomarker discovery.
*    Integrate publicly or commercially available genomic data with novel experimental data.
*    Identify and execute innovations (computational, statistical, and strategic) that will quantifiably improve Projects
*    Identify new datasets and data mining techniques relevant to cancer target and drug discovery
*    Develop and test novel methods and algorithms, working with academic collaborators where opportunities arise

Qualifications & Requirements
*         PhD in Biology, Bioinformatics, or equivalent, as well as 2+years of full time experience in an academic or biotechnology industry lab, or equivalent experience.
*         Interest in, and working knowledge of cancer biology,
*         A solid understanding of statistics. Have experience with a broad range of statistical methods for classification and prediction, e.g., linear models, machine learning, and other multivariate analysis methods.
*         Programming experience and ability to write R and Perl script.
*         The candidate will have experience with large-scale genomics data and a solid understanding of bioinformatics data bases (eg: GenBank, RefSeq, dbSNP etc)
*         Experience with some bioinformatics software such as: Spotfire, Partek, Ingenuity, GeneGo, Balst, and Blat.
*         The candidate will have the ability and interest in learning new techniques and skills in accordance with evolving research program needs.
*         Candidates with a proven ability to work efficiently in a team setting, and excellent communication skills are preferred. 

About AVEO
AVEO Pharmaceuticals (NASDAQ: AVEO) integrates a proprietary cancer biology platform with drug development and commercial expertise in its efforts to discover and develop targeted cancer therapeutics. The company's lead product, Tivozanib, is an oral, triple VEGF receptor inhibitor with potential for a best-in-class profile. Tivozanib is currently being investigated in a global, randomized Phase 3 clinical trial called TIVO-1  comparing Tivozanib to Sorafenib in advanced kidney cancer, as well as additional clinical studies in other solid tumor types. AVEO's proprietary, integrated cancer biology platform offers the company a unique advantage in oncology drug development that both increases the probability of clinical success and provides a discovery engine for high-value targets.
This approach has resulted in a promising pipeline of monoclonal antibodies against novel targets including HGF, ErbB3, RON, Notch and FGFR.
For more information, please visit the company's website at www.aveopharma.com.

Please forward resumes to hr at aveopharma.com

AVEO is an Equal Employment Opportunity employer that values the strength diversity brings to the workplace.

posted 2010.07.20